FSD Pharma Inc. - Class B Subordinate Voting Shares (NQ:HUGE)

0.0899 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FSD Pharma Inc. - Class B Subordinate Voting Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

September 13, 2023

Via ACCESSWIRE

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)

August 25, 2023

From FSD Pharma Inc.

Via Business Wire

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present Phase 1 Data on Lucid-MS at Milan Peer Conference

August 15, 2023

Via Investor Brand Network

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

August 15, 2023

Via ACCESSWIRE

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

August 03, 2023

Via Investor Brand Network

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

August 03, 2023

Via Investor Brand Network

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD

August 02, 2023

Via Investor Brand Network

FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

August 02, 2023

Via ACCESSWIRE

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

July 18, 2023

Via Investor Brand Network

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201

July 17, 2023

From FSD Pharma Inc.

Via Business Wire

FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock

July 10, 2023

From FSD Pharma Inc.

Via Business Wire

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors

July 04, 2023

From FSD Pharma Inc.

Via Business Wire

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Shares Results Shareholder Annual General and Special Meeting

June 30, 2023

Via Investor Brand Network

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

June 30, 2023

From FSD Pharma Inc.

Via Business Wire

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) Featured in InvestmentPitch Media Video

June 23, 2023

Via Investor Brand Network

FSD Pharma Announces Agreement To Grant Exclusive Rights To Recreational Alcohol Misuse Technology ↗

June 20, 2023

Via Benzinga

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Grant Exclusive Rights to Recreational Alcohol Misuse Technology

June 20, 2023

Via Investor Brand Network

FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology

June 20, 2023

From FSD Pharma Inc.

Via Business Wire

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Board Appointment of Dr. Eric Hoskins

May 25, 2023

Via Investor Brand Network

FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors

May 25, 2023

From FSD Pharma Inc.

Via Business Wire

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

May 16, 2023

Via Investor Brand Network

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗

May 15, 2023

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.